Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by inthnoon May 30, 2024 7:34pm
121 Views
Post# 36065459

RE:RE:what's Rigby is up to

RE:RE:what's Rigby is up to
Rigby and Parsons are both on the bod for Sernova. What people need to know is this is how the bod makes their living is by being on multiple boards and getting paid and options and only required to meet about 4 times a year or so when it comes to quarterly reporting and year end.

Also of note and IMO is now that we know we have a new senior officer coming on board and from California this most likely means that it will be a partnership as opposed to a buyout at this time as if there was a BO on the table then they would not have had to hire the new person and give 200,000 options.

It should HOPEFULLY come together soon as of the end of May we have the 2 year OS for bracelet mbc and gcar shortly and then the FDA type C meeting. This should put everything in line for a partnership for as the company to go forward they will need funds so would either be a partnership or money raise and let's hope that it is better than the AN deal which did nothing for the company.
<< Previous
Bullboard Posts
Next >>